Search for content, post, videos

She is the new Chief Technology Officer at Alligator

Alligator Bioscience has announced the promotion of Laura von Schantz to Chief Technology Officer, and her joining the executive management team.

In this role, she will oversee all technical aspects in the development of Alligator’s preclinical and clinical pipeline, including lead assets mitazalimab, a CD40 agonist currently in Phase 2 clinical development, and ATOR-1017, a Phase 2-ready 4-1BB agonist.

“It’s with great pleasure that we welcome Laura to her new role as Alligator’s Chief Technology Officer and part of our executive management team,” says Søren Bregenholt, CEO of Alligator Bioscience. “Laura is the natural choice for the role to drive continued development of Alligators technology platforms, while at the same time ensure we deliver on our internal and partnered discovery programs. She has a deep knowledge of the company and our past scientific achievements and future goals. Laura steps into the role at a pivotal time for Alligator as we prepare to advance and expand our preclinical and clinical pipeline and we will benefit greatly from her knowledge and expertise.”

Laura von Schantz

Laura joined Alligator in 2014 and was most recently Vice President, Discovery, a position she held since January 2021 and in which she played a key role in securing Alligator’s research agreements most recently with Orion Corporation, as well as restructuring and invigorating the company’s Discovery function, describes the company. Prior to that, Laura was Director, Antibody Engineering where she was responsible for Alligator’s technology platform.

During her time with the company, Laura has also been instrumental in the invention of Alligator’s RUBY bispecific format and has led the establishment of antibody engineering that can generate functional and developable candidate drugs at a competitive pace. She holds a PhD in Immuno-technology and an MSc in Biotechnology, both from Lund University.

“The use of cutting-edge technology is a core part of Alligator’s innovative scientific approach, and I am very excited to be assuming this vital role,” says Laura von Schantz, CTO of Alligator Bioscience. “I am extremely proud of the recent advancements of our clinical and preclinical programs, and I look forward to continuing my contribution to the company’s goal of developing meaningful therapies for patients with hard-to-treat cancers.”

Photo: Alligator Bioscience